Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-29T00:47:45.864Z Has data issue: false hasContentIssue false

P0294 - Remission in schizophrenia: 1 year Italian study with risperidone long-acting injectable (RLAI) in subjects with schizophrenia or schizoaffective disorder

Published online by Cambridge University Press:  16 April 2020

A. Rossi
Affiliation:
Department of Experimental Medicine - University of L'Aquila, Aquila, Italy
M.M. Bernareggi
Affiliation:
Risperidone Long-Acting Trial Italian Investigators (R-LAI), Medical Affairs, Janssen-Cilag SpA, Cologno Monzese, Milano, Italy
M.G. Giustra
Affiliation:
Risperidone Long-Acting Trial Italian Investigators (R-LAI), Medical Affairs, Janssen-Cilag SpA, Cologno Monzese, Milano, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Actual treatment outcomes are directed towards preventing relapses, instead of new perspective of functional recovery feasible with the achievement of a prolonged remission which is defined, according to Andreasen1, in severity criteria: PANSS items (P1, P2, P3, G5, G9, N1, N4, N6) scores <3 and duration criteria (maintenance of score for at least 26 weeks) here applied to 243 subjects with schizophrenia or schizoaffective disorder treated for 1 year with RLAI.

Results:

Although subjects were stable, only 14% of them met the PANSS severity criterion for remission at baseline with an increase to 45% after 1 year. 63% of subjects who were in remission at baseline maintained the criterion at the end of the study, while the 26% of subjects not in remission at baseline reached the criterion after 1 year. In addition, 32% of subjects met both severity and duration criteria for remission at 12 months. The decrease in PANSS total score from baseline (88.4+22.0) to 12 months (69.6+22.9; p<0.001) is associated to the remission (Chi Square test, p<0.001). At baseline, the difference in CGI-S and GAF scores between remitted subjects and non remitted is significant (p<0.001). In remitted subjects, the improvement in PANSS cognitive factor is higher (p<0.001) than that observed in non remitted subjects.

Conclusions:

This study shows that RLAI treatment up to 1 year warrants efficacy maintenance with a significant and sustained symptom improvement, enabling the subjects to achieve and maintain the remission criteria for schizophrenia.

Type
Poster Session I: Neuroleptics and Antipsychotics
Copyright
Copyright © European Psychiatric Association 2008

References

Andreasen, et al. Am J Psychiatry 2005, 162: 441–910.1176/appi.ajp.162.3.441CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.